Previous Article | Next Article 
Infection and Immunity, August 2001, p. 5166-5172, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5166-5172.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Role of Gingipains in Growth of Porphyromonas
gingivalis in the Presence of Human Serum Albumin
Daniel
Grenier,1,*
Sandra
Imbeault,1
Pascale
Plamondon,1
Gilbert
Grenier,1
Koji
Nakayama,2 and
Denis
Mayrand3
Groupe de Recherche en Écologie
Buccale, Faculté de Médecine
Dentaire,1 and Faculté des
Sciences et de Génie,3
Université Laval, Québec City, Québec,
Canada, and Department of Microbiology, School of
Dentistry, Nagasaki University, Nagasaki 852-8588, Japan2
Received 5 February 2001/Returned for modification 15 March
2001/Accepted 5 May 2001
 |
ABSTRACT |
Porphyromonas gingivalis, a bacterium associated with
active chronic periodontitis lesions, produces several proteolytic
enzymes that are thought to be involved in host colonization,
perturbation of the immune system, and tissue destruction. The aim of
the present study was to investigate the contribution of Arg- and
Lys-gingipains produced by P. gingivalis to its growth.
Although all of the proteins studied were degraded by P. gingivalis, only human serum albumin and transferrin supported
growth during serial transfers in a chemically defined medium (CDM).
Growth studies with site-directed gingipain-deficient mutants of
P. gingivalis revealed that inactivation of both gingipains
prevents growth, whereas inactivation of either Arg- or Lys-gingipain
activity extended the doubling times to 33 or 13 h, respectively,
compared to 9 h for the parent strain. Growth of the mutants and
the parent strain was similar when the CDM was supplemented with a
protein hydrolysate instead of human serum albumin. Incubation of
resting P. gingivalis ATCC 33277 cells with
fluorophore-labeled albumin indicated that the proteolytic fragments
generated by the gingipains were internalized by the bacterial cells.
Internalization of fluorophore-labeled albumin fragments was reduced or
completely inhibited in the proteinase-deficient mutants.
Interestingly, gingival crevicular fluid samples from diseased
periodontal sites contained low-molecular-mass albumin fragments,
whereas samples from healthy sites did not. The critical role of
proteinases in the growth of P. gingivalis was further investigated using specific Arg- and Lys-gingipain inhibitors. Adding
the inhibitors to CDM containing albumin revealed that leupeptin
(Arg-gingipain A and B inhibitor) was more efficient at inhibiting
growth than cathepsin B inhibitor II (Lys-gingipain inhibitor). Our
study suggests that Arg-gingipains and, to a lesser extent,
Lys-gingipain play an important role in the growth of P. gingivalis in a defined medium containing a human protein as the
sole carbon and nitrogen source.
 |
TEXT |
Gram-negative anaerobic bacteria
play an important role in the initiation and progression of
periodontitis. More particularly, Porphyromonas gingivalis
has been strongly associated with active chronic periodontitis lesions
(24). This bacterial species produces several proteinases
that are thought to be involved in host colonization, perturbation of
the immune system, and tissue destruction (10, 12, 15).
Most of the proteolytic activity exhibited by P. gingivalis
is due to Arg- and Lys-gingipain cysteine proteinases (3, 12,
15). Two different genes code for the arginine-X (Arg-gingipain
A [rgpA] and B [rgpB])-specific cysteine
proteinases, whereas one gene codes for the lysine-X (Lys-gingipain
[kgp])-specific cysteine proteinase (3). By
cleaving a variety of host proteins, these proteinases may provide
small peptides and amino acids that meet the nutritional requirements
of P. gingivalis (7, 22) and may thus
participate in the pathogenic process of periodontitis. The critical
role of P. gingivalis proteinases in pathogenicity is
supported by the fact that immunization with purified Arg-gingipain A
or B protects against colonization and invasion of a mouse chamber model by P. gingivalis (6, 21). There is also
evidence indicating that P. gingivalis proteinases are
expressed in periodontal sites, since serum immunoglobulin G responses
in patients suffering from periodontitis indicate that P. gingivalis proteinases are important antigens (5,
11).
The gingival crevicular fluid bathing periodontal pockets contains a
variety of proteins, including albumin, transferrin, and immunoglobulin
G (4, 16). We showed in a previous study (2)
that human transferrin may be a source of iron for supporting the
growth of P. gingivalis and that cysteine proteinases, and more particularly Lys-gingipain, are critical in the acquisition of
iron from this protein. No clear evidence is currently available concerning potential sources of peptides and amino acids for P. gingivalis in subgingival sites or the role played by Arg- and Lys-gingipains in producing these nutrients from human proteins. The
aims of the present study were to investigate whether various human
proteins could serve as sources of peptides and amino acids for
P. gingivalis and to determine the contribution of Arg- and Lys-gingipains to the growth of P. gingivalis in a
chemically defined medium (CDM) supplemented with human serum albumin
as the sole source of carbon and nitrogen.
Six strains of P. gingivalis were used in the study: ATCC
33277, ATCC 49417, and W50, as well as three proteinase-deficient mutants (KDP129, KDP112, and KDP128) derived from ATCC 33277. The
construction of these mutants using suicide plasmids has been previously reported (20, 23). KDP129 is a kgp
(Lys-gingipain) mutant, KDP112 is a rgpA rgpB
(Arg-gingipains A and B) double mutant, and KDP128 is a rgpA rgpB
kgp (Arg- and Lys-gingipains) triple mutant. Bacteria were
maintained by weekly transfers on Todd-Hewitt agar plates (BBL
Microbiology Systems, Cockeysville, Md.) supplemented with hemin (10 µg/ml), vitamin K (1 µg/ml), and sheep blood (5% [vol/vol]). To
prevent the appearance of revertants and to ensure the correct
genotype, KDP112 and KDP128 were cultivated in the presence of
tetracycline (0.7 µg/ml) and erythromycin (10 µg/ml). All cultures
were incubated at 37°C in an anaerobic chamber (N2H2CO2, 75:10:15). Prior to using
the mutants in the experiments described below, their phenotypes were
confirmed by testing their ability to cleave chromogenic substrates for
Arg-gingipain (benzoyl-arginine-p-nitroanilide) and
Lys-gingipain
(N-p-tosyl-glycine-proline-lysine-p-nitroanilide) as previously described (2).
Growth studies were carried out in the CDM previously described by
Milner et al. (19), which contains
NaH2PO4 (10 mM), KCl (10 mM), MgCl2
(1.2 mM), ZnCl2 (25 mM), CaCl2 (20 mM),
CoCl2 (10 mM), CuCl2 (5 mM), NaMoO4
(0.1 mM), boric acid (5 mM), citric acid (2 mM),
-ketoglutarate (50 mM), hemin (7.5 µM), and vitamin K (3 µM). The medium was adjusted
to pH 7 and sterilized by filtration (0.22 µm [pore size]). It was
supplemented with 3% of either a protein or a protein hydrolysate. The
proteins used were human serum albumin, human transferrin (30% iron
saturated), human immunoglobulin G, and calf skin type I soluble
collagen. All were obtained from Sigma Chemical Co. (St. Louis, Mo.).
The protein hydrolysates used were pancreatic hydrolysate of casein
(BBL Microbiology Systems) and proteolytic hydrolysate of chicken egg
albumin (Sigma Chemical Co.). The final maximum optical densities at
660 nm (OD660) reached by the cultures were recorded. In
terms of dry weight, a value of 1.0 at OD660 in CDM
supplemented with either 3% human serum albumin or 3% pancreatic
hydrolysate of casein corresponds to 1.1 ± 0.08 or 0.92 ± 0.04 mg/ml, respectively. When growth occurred, the cultures were
transferred (1% [vol/vol] inoculum) to the corresponding medium up
to four times. Growth of strain ATCC 33277 and the proteinase-deficient mutants (KDP112, KDP129, and KDP128) in CDM containing human serum albumin was followed by recording the OD660 at various
times during the incubation. The doubling times were calculated by
regression analysis of the OD660 values from the
exponential phase of growth.
Mutant KDP129 was used to prepare a purified fraction containing
Arg-gingipains (rgpA and rgpB), whereas KDP112
was used to isolate Lys-gingipain (kgp). The use of these
mutants facilitated the purification of the gingipains, which are
difficult to separate from one another. Bacteria were grown (48 h) in 2 liters of Todd-Hewitt broth containing hemin and vitamin K. The cells
were harvested by centrifugation at 8,000 × g for 15 min, washed twice with 50 mM phosphate-buffered saline (PBS; pH 7.2),
and resuspended in 50 ml of the same buffer. The suspensions were
sonicated (8 min, 60% duty cycle, output 6; Sonifier Cell Disrupter
W-350; Branson Sonic Power Co.), and unbroken cells and cellular debris
were removed by centrifugation at 8,000 × g for 15 min. Membranes (cytoplasmic and outer) were pelleted by centrifugation
of the supernatant at 120,000 × g for 1 h at
4°C and resuspended in 10 ml of 50 mM Tris-HCl (pH 8.2) prior to
adding CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} to a
final concentration of 0.5%. The membrane suspension was stirred
overnight at 4°C and then centrifuged at 120,000 × g
for 1 h at 4°C. The supernatant containing the soluble membrane
fraction was kept at
20°C until used. Solubilization of the
pelleted membranes with 0.5% CHAPS was repeated until no residual Arg-
or Lys-gingipain activity could be detected in the soluble fraction.
The soluble membrane fractions were pooled and dialyzed (molecular mass
cutoff of 6,000 to 8,000 Da) overnight at 4°C against 2 volumes of 50 mM Tris-HCl (pH 7.4) containing 200 mM NaCl. The gingipains were purified by affinity chromatography on arginine-Sepharose 4B (Amersham Pharmacia Biotech, Baie d'Urfé, Quebec, Canada) as previously described (8). Arg- and Lys-gingipain activities were
quantified using benzoyl-arginine-p-nitroanilide and
N-p-tosyl-glycine-proline-lysine-p-nitroanilide, respectively. One unit of enzyme was defined as the amount required to
release one nanomole of p-nitroaniline per hour.
Protein degradation by P. gingivalis was tested using
bacterial suspensions (OD660 = 2.0 in PBS) prepared from
24-h Todd-Hewitt broth cultures. Mixtures containing bacteria (20 µl), protein (10 µl; 1 mg/ml), PBS (20 µl), and dithiothreitol
(10 µl; 10 mM) were incubated at 37°C for 30 min, 1, 2, and 4 h. An equal volume of electrophoresis sample buffer was then added, and
the mixtures were boiled prior to analysis by sodium dodecyl sulfate
(SDS)-12.5% (11% for collagen analysis) polyacrylamide gel
electrophoresis (PAGE) according to the procedure of Laemmli
(14). In the case of albumin, transferrin, and
immunoglobulin G, undegraded proteins and protein fragments were
electrophoretically transferred onto a nitrocellulose membrane and
detected using alkaline phosphatase-conjugated goat anti-human albumin
antibody (1/8,000 dilution), alkaline phosphatase-conjugated goat
anti-human transferrin antibody (1/3,000 dilution), and alkaline
phosphatase-conjugated goat anti-human immunoglobulin G antibody
(1/3,000 dilution), respectively. The antibodies were obtained from
Bethyl Laboratories, Inc. (Montgomery, Tex.). Undegraded proteins and
fragments were visualized following development in carbonate buffer
containing 0.3 mg of NBT and 0.15 mg of BCIP
(5-bromo-4-chloro-3-indolylphosphate) per ml. The degradation of calf
skin type I collagen was determined by using 14C-labeled
substrate (18). Following incubation with bacterial cells,
the collagen was analyzed by SDS-PAGE and autofluorography. Lastly, the
degradation of human serum albumin by the Arg- and Lys-gingipain
preparations was evaluated as described above except that the bacterial
suspensions were replaced by 312 U of enzyme.
The uptake of albumin degradation products by P. gingivalis
ATCC 33277 and the three proteinase-deficient mutants was tested using
24-h Todd-Hewitt broth cultures. Self-quenched DQ green bovine serum
albumin (Molecular Probes, Eugene, Oreg.) was used. Degradation
products emitted maximally at 515 nm following excitation at 505 nm.
The assay mixture contained bacteria (100 µl of the culture), PBS (80 µl; O2-free), and DQ albumin (20 µl; 200 µg/ml). Heat-treated P. gingivalis cultures were used as controls.
In one experiment, proteinase K (100 µg/ml) was used instead of
bacterial cells. Assay mixtures were incubated at 37°C for 3 h
under darkness prior to recovering the cells by centrifugation
(6,000 × g, 10 min). The fluorescence of the
supernatant, which indicated the degree of albumin degradation, was
measured using a fluorometer at excitation and emission wavelengths of
490 and 520 nm, respectively. The cell pellet was thoroughly washed
twice in PBS and resuspended in 100 µl of 0.05% SDS to lyse the
bacteria and allow the internal fluorescence, which corresponded to
bovine serum albumin fragments incorporated by P. gingivalis
to be measured. The fluorescence results were expressed as relative
fluorescence units (RFU).
The effect of cathepsin B inhibitor II (Calbiochem, San Diego, Calif.)
and leupeptin (Sigma Chemical Co.), which have been shown to be
specific inhibitors of Lys- and Arg-gingipain activities, respectively
(2), on the degradation of human serum albumin by P. gingivalis ATCC 33277 was verified by adding them (10 µM) to the
assay mixture described above. Their effect on the growth of P. gingivalis ATCC 33277 in CDM containing either human serum albumin
or pancreatic hydrolysate of casein was also tested. Twofold serial
dilutions of the inhibitors were tested beginning with an initial
concentration of 20 µM.
Gingival crevicular fluid samples were obtained from 24 patients
attending the dental clinic at Université Laval. The pocket depth
of each site was measured using a Michigan 0 periodontal probe.
Patients were distributed into three categories: healthy (pocket depth
of
3 mm), moderate periodontitis (pocket depth of between 4 and 6 mm), and advanced periodontitis (pocket depth of
7 mm). Paper strips
(3MM; 2 by 8 mm) were inserted into the subgingival sites for 30 s. The strips were then placed in 250 µl of PBS containing a protease
inhibitor cocktail with a broad inhibitory spectrum (complete mini
#1836153; Roche Diagnostics, Laval, Québec, Canada) and frozen at
20°C. To recover the adsorbed proteins, the samples were thawed
rapidly at room temperature and shaken at 4°C for 2 h. The paper
strips were then removed, and the samples were kept frozen until used.
A 10-µl volume of gingival crevicular fluid sample was mixed with 10 µl of electrophoresis sample buffer and boiled for 10 min. Proteins
were separated on 12.5% polyacrylamide gels according to the method of
Laemmli (14) and then electrophoretically transferred onto
a nitrocellulose membrane. The membranes were incubated with alkaline
phosphatase-conjugated goat anti-human albumin antibody (1/8,000
dilution) for 2.5 h. Albumin and albumin fragments were visualized
as described above.
The four proteins selected for the growth studies (albumin,
transferrin, immunoglobulin G, and collagen) were first tested for
their susceptibility to proteolytic degradation by resting P. gingivalis cells. As shown in Fig.
1, all of the proteins
were degraded to various degrees. Albumin and collagen are completely degraded after 4 h. Transferrin and immunoglobulin G appear to be
slightly less susceptible since some protein remains undegraded and
there is an accumulation of proteolytic fragments. The fact that
albumin, transferrin, immunoglobulin G, and collagen are partially or
totally degraded by P. gingivalis suggests that they may be
potential sources of peptides and amino acids suitable for the growth
of this bacterial species. The proteins were individually added to the
CDM to determine their ability to support the growth of P. gingivalis ATCC 33277. Human serum albumin and human transferrin supported the growth (final maximal OD660 of >0.8; 48 h of incubation) of P. gingivalis for up to four serial
transfers. On the other hand, immunoglobulin G and collagen did not
support the growth of P. gingivalis, even after a prolonged
incubation period of 72 h (final maximal OD660 of
<0.1). These results indicate that the ability of P. gingivalis to hydrolyze proteins does not necessarily imply that
these proteins can be used by the bacterium to support its growth.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Degradation of human serum albumin (gel A), human
transferrin (gel B), human immunoglobulin G (gel C), and calf skin type
I collagen (gel D) by P. gingivalis ATCC 33277. Gels A, B,
and C: lane 1, molecular mass markers (myosin [206 kDa],
-galactosidase [117 kDa], bovine serum albumin [79 kDa],
ovalbumin [48 kDa], carbonic anhydrase [34.7 kDa], soybean trypsin
inhibitor [29 kDa], lysozyme [21 kDa]); lane 2, protein without
cells; lane 3, protein incubated with cells for 30 min; lane 4, protein
incubated with cells for 1 h; lane 5, protein incubated with cells
for 2 h; lane 6, protein incubated with cells for 4 h. Gel D:
lane 1, protein without cells; lane 2, protein incubated with cells for 30 min; lane 3, protein incubated
with cells for 2 h; lane 4, protein incubated with cells for
4 h. Degradation of albumin, transferrin, and immunoglobulin G was
determined by SDS-PAGE and Western immunoblotting analysis. Degradation
of collagen was determined by SDS-PAGE and autofluorography.
|
|
Since albumin is the predominant protein in the gingival crevicular
fluid bathing periodontal pockets (4) and also supports the growth of P. gingivalis in a CDM with no other sources
of peptides and amino acids, it was selected for further growth
studies. The doubling times of three laboratory strains of P. gingivalis (ATCC 33277, ATCC 49417, and W50) in CDM supplemented
with serum albumin were 9.2, 9, and 5.4 h, respectively. The fact
that strain W50 grew much better may be related to a more efficient
degradation of serum albumin, to a lower peptide requirement, or to a
more efficient system of peptide transport. Phase-contrast microscopic observations showed that P. gingivalis grew in large cell
aggregates in CDM containing serum albumin, whereas isolated or
short-chain coccobacilli were observed in Todd-Hewitt broth (data not
shown). It is possible that albumin receptors on the cell surface of
P. gingivalis could favor the phenomenon of aggregation.
Growth curves of P. gingivalis ATCC 33277 and the three
proteinase-deficient mutants in CDM containing serum albumin are
presented in Fig. 2. The ability to use
albumin as a carbon and nitrogen source as well as doubling times
varied considerably depending on the missing proteinase activity. The
doubling times of mutants KDP129 (kgp) and KDP112
(rgpA rgpB) were 13 and 33 h, respectively, whereas that of the parent strain (ATCC 33277) was 9 h. The final maximum OD660 reached by mutant KDP129 was similar to that of the
parent strain. On the other hand, mutant KDP112 grew to a maximum
OD660 of 0.16. Mutant KDP128 (kgp rgpA rgpB) did
not grow in CDM containing serum albumin, suggesting that proteinase
activity is essential for the growth of P. gingivalis. The
effect of a deficiency in Arg- and/or Lys-gingipain activity on the
growth of P. gingivalis in the presence of a protein
hydrolysate rather than serum albumin was investigated. Growth was not
affected by the absence of proteinase activities when the CDM was
supplemented with either a pancreatic hydrolysate of casein or a
proteolytic hydrolysate of egg albumin. These two hydrolysates gave
OD660 ranging from 1.3 to 1.6 for all strains (data not
shown).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Growth curves of P. gingivalis ATCC 33277 and
proteinase-deficient mutants KDP112 (rgpA rgpB), KDP129
(kgp), and KDP128 (rgpA rgpB kgp) in a CDM
supplemented with human serum albumin.
|
|
In order to establish a correlation between the growth of P. gingivalis in CDM containing serum albumin and the ability to degrade the protein, strain ATCC 33277 and the proteinase-deficient mutants were incubated with serum albumin for 2 h. Protein
degradation was monitored by SDS-PAGE and Western immunoblotting
analysis (Fig 3A). Mutant KDP128, which
did not grow in CDM supplemented with serum albumin, was unable to
degrade the protein. Mutants KDP112 and KDP129 were slightly less
effective than the parent strain in hydrolyzing the albumin. Several
bands produced by these mutants appeared to have similar molecular
masses. The susceptibility of human serum albumin to purified
preparations of Arg- and Lys-gingipains is reported in Fig. 3B. After a
2-h incubation, the Lys-gingipain preparation yielded more fragments
than the preparation containing Arg-gingipains A and B. Fragments
produced by the Arg- and Lys-gingipain preparations differed slightly
in their molecular masses. When the incubation was extended to 4 h, a more pronounced degradation of albumin was observed with the
Lys-gingipain preparation than the Arg-gingipain A and B preparation.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 3.
Degradation of human serum albumin by resting P. gingivalis cells (A) and purified preparations of gingipains (B),
as determined by SDS-PAGE and Western immunoblotting analysis. Gel A:
lane 1, molecular mass markers (myosin [206 kDa], -galactosidase
[117 kDa], bovine serum albumin [79 kDa], ovalbumin [48 kDa],
carbonic anhydrase [34.7 kDa], soybean trypsin inhibitor [29 kDa],
lysozyme [21 kDa]); lane 2, albumin without cells; lane 3, albumin
incubated with ATCC 33277 for 2 h; lane 4, albumin incubated with
KDP112 (rgpA rgpB) for 2 h; lane 5, albumin incubated
with KDP128 (rgpA rgpB kgp) for 2 h; lane 6, albumin
incubated with KDP129 (kgp) for 2 h. Gel B: lane 1, molecular mass markers (myosin [206 kDa], -galactosidase [117
kDa], bovine serum albumin [79 kDa], ovalbumin [48 kDa], carbonic
anhydrase [34.7 kDa], soybean trypsin inhibitor [29 kDa], lysozyme
[21 kDa]); lane 2, albumin incubated with the preparation of
Arg-gingipains for 2 h; lane 3, albumin incubated with the
preparation of Arg-gingipains for 4 h; lane 4, albumin incubated
with the preparation of Lys-gingipain for 2 h; lane 5, albumin
incubated with the preparation of Lys-gingipain for 4 h; lane 6, albumin alone.
|
|
The ability of P. gingivalis to grow in CDM containing serum
albumin implies that the bacterium cleaves the protein and assimilates the degradation products, which it then uses as a source of carbon and
nitrogen. This was investigated using fluorophore-labeled bovine serum
albumin and monitoring the uptake of fluorescence (Table
1). Substantial hydrolysis of the
substrate occurred with the parent strain, whereas only partial
degradation occurred with mutants KDP112 and KDP129. Mutant KDP128,
which is deficient in both Arg- and Lys-gingipain activities, released
no fluorescence, indicating that no degradation occurred. When cells
incubated with fluorophore-labeled albumin were washed extensively to
remove surface-associated fluorescence and lysed with SDS, high levels of intracellular fluorescence were detected with the parent strain. No
fluorescence was detected when cells were not lysed, suggesting intracellular uptake rather than cell surface binding of fluorescent peptides. Mutants KDP112, KDP129, and KDP128 internalized approximately 66, 27, and 5%, respectively, of the fluorescence internalized by the
parent strain. The fact that mutant KDP112 assimilated more serum
bovine albumin-derived peptides than mutant KDP129 but grew poorly
compared to this mutant in CDM supplemented with human serum albumin
may be related to the different sources of albumin used. It is also
possible that the albumin-derived peptides assimilated by mutant KDP112
may not be appropriate to support growth.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Uptake of fluorescence from fluorophore-labeled bovine
serum albumin by P. gingivalis ATCC 33277, KDP112,
KDP129, and KDP128.
|
|
The importance of proteinases for the growth of P. gingivalis was further investigated using specific Arg- and
Lys-gingipain inhibitors. Although the inhibition was not complete, 10 µM leupeptin (Arg-gingipain A and B inhibitor) reduced the
degradation of serum albumin by resting P. gingivalis ATCC
33277 cells more effectively than 10 µM cathepsin B inhibitor II
(Lys-gingipain inhibitor), as determined by SDS-PAGE and Western
immunoblotting analysis (data not shown). The inhibitors were also
added to CDM supplemented with serum albumin to investigate their
ability to inhibit the growth of P. gingivalis ATCC 33277. Leupeptin was more effective at inhibiting growth than cathepsin B
inhibitor II. Inhibition by 5 µM leupeptin exceeded 90%, while
inhibition by 20 µM cathepsin B inhibitor II only reached 44%. No
inhibition occurred when the CDM was supplemented with pancreatic
hydrolysate of casein instead of serum albumin. Inhibition of the
growth of P. gingivalis by other proteinase inhibitors
(cystatin and bestatin) has been previously reported (1,
13). These inhibitors appear to affect the growth of P. gingivalis by interfering with peptide transport rather than by
inactivating gingipain activities.
Finally, gingival crevicular fluid samples from patients with various
periodontal conditions were analyzed for the presence of serum albumin
fragments as an indication of the degradation of this protein in vivo
(Fig. 4). Gingival crevicular fluid
samples from healthy periodontal sites contained serum albumin but no detectable proteolytic fragments. On the other hand, numerous low-molecular-mass albumin fragments were found in samples from patients with periodontitis, more particularly those from periodontal pockets greater than or equal to 7 mm in depth. The degradation products detected in gingival crevicular fluid may be produced by
P. gingivalis, other proteolytic bacteria, or host
proteinases. In vivo, the degradation of albumin, in addition to
providing peptides, which can serve as carbon and nitrogen sources, may also result in the liberation of heme, which is scavenged and transported by this serum protein.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
SDS-PAGE Western immunoblotting analysis of gingival
crevicular fluid samples for the presence of albumin and albumin
fragments. Lanes 1, molecular mass markers (myosin [206 kDa],
-galactosidase [117 kDa], bovine serum albumin [79 kDa],
ovalbumin [48 kDa], carbonic anhydrase [34.7 kDa], soybean trypsin
inhibitor [29 kDa], lysozyme [21 kDa]); lanes 10, control human
serum diluted 1 in 500. Gel A, samples (lanes 2 to 9) from healthy
periodontal sites; Gel B, samples (lanes 2 to 9) from periodontal
pockets with depths ranging from 4 to 6 mm; Gel C, samples (lanes 2 to
9) from periodontal pockets with depths ranging from 7 to 12 mm.
|
|
Previous studies (4, 9) have shown that serum albumin is a
key protein in gingival crevicular fluid and may thus be utilized for
supporting the growth of asaccharolytic periodontopathogens in
subgingival sites. Indeed, increased albumin concentrations in saliva
and gingival crevicular fluid during inflammation and periodontal
tissue destruction have been reported (4, 9). Evidence
suggesting the degradation of albumin in vivo in periodontal pockets
was obtained in the present study. The degradation of bovine albumin
and hemalbumin by P. gingivalis has been extensively studied
by Smalley and Birss (25). They reported the production of
protease-stable 55.6-kDa peptides and noted that the total amount of
hemalbumin degraded decreased with an increase in the ratio of bound
hemin. Heme binding thus appears to protect albumin against proteolysis
by P. gingivalis. Heme saturation of albumin in gingival
crevicular fluid has not been reported yet.
Our results suggest that Arg-gingipains play a key role in the growth
of P. gingivalis in a CDM containing human serum albumin as
the sole source of carbon and nitrogen. This is supported by the fact
that (i) a mutant deficient in Arg-gingipains did not grow optimally
and (ii) a specific Arg-gingipain inhibitor (leupeptin) prevented
growth. On the other hand, we found that proteinases are not required
for growth in a CDM containing a protein hydrolysate (casein or egg
albumin) instead of a whole protein. Shi et al. (23)
reported that an Arg-gingipain A and B null mutant could grow in a
defined medium containing bovine serum albumin just as well as the wild
type. This discrepancy with our results is likely related to the types
of albumin (human and bovine) used, which may have different
susceptibilities to P. gingivalis gingipains.
Results from the present study have provided a better understanding of
the roles of Arg- and Lys-gingipains in the growth of P. gingivalis. Arg-gingipains but not Lys-gingipain appear to be
essential when protein sources other than amino acids or low-molecular-weight peptides are provided. We hypothesize that the
action of Arg-gingipains generate peptides with C-terminal arginine
residues from albumin. Once assimilated by bacteria, an arginine
carboxypeptidase previously characterized from P. gingivalis
can liberate C-terminal arginine from these peptides (17).
The arginine could then be catabolized via an arginine deiminase
pathway as in lactic bacteria (26). This pathway involves three enzymes (arginine deiminase, ornithine transcarbamylase, and
carbamate kinase) and results in the production of ornithine, ammonia,
carbon dioxide, and ATP. Further studies to investigate this pathway in
P. gingivalis should be carried out. Since healthy subgingival sites do not appear to contain serum albumin fragments, P. gingivalis proteinases may be even more important in the
initiation phase of periodontitis. The local application of gingipain
inhibitors might suppress gingipain activities and thus the production
of peptides that may be used to support the growth of P. gingivalis. However, it is likely that any periodontal therapy
based on the local application of gingipain inhibitors would have only
a limited effect on P. gingivalis in the case of advanced
periodontitis, a condition where serum albumin fragments are present in
large quantity.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Canadian Institutes
of Health Research, FRSQ, Fonds FCAR, and Fonds Emile-Beaulieu.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Groupe de
Recherche en Écologie Buccale, Université Laval,
Québec City, Québec, Canada G1K 7P4. Phone: (418) 656-7341. Fax: (418) 656-2861. E-mail: Daniel.Grenier{at}greb.ulaval.ca.
Editor:
W. A. Petri Jr.
 |
REFERENCES |
| 1.
|
Blankenvoorde, M. F. J.,
W. van't Hof,
E. Walgreen-Weterings,
T. J. M. van Steenbergen,
H. S. Brand,
E. C. I. Veerman, and A. V. Nieuw Amerongen.
1998.
Cystatin and cystatin-derived peptides have antibacterial activity against the pathogen Porphyromonas gingivalis.
Biol. Chem.
379:1371-1375[Medline].
|
| 2.
|
Brochu, V.,
D. Grenier,
K. Nakayama, and D. Mayrand.
2001.
Acquisition of iron from human transferrin by Porphyromonas gingivalis: a role for Arg- and Lys-gingipain activities.
Oral Microbiol. Immunol.
16:79-87[CrossRef][Medline].
|
| 3.
|
Curtis, M. A.,
H. K. Kuramitsu,
M. Lantz,
F. L. Macrina,
K. Nakayama,
J. Potempa,
E. C. Reynolds, and J. Aduse-Opoku.
1999.
Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis.
J. Periodontal Res.
34:464-472[CrossRef][Medline].
|
| 4.
|
Curtis, M. A.,
J. A. C. Sterne,
S. J. Price,
G. S. Griffiths,
S. K. Coulthurst,
J. M. A. Wilton, and N. W. Johnson.
1990.
The protein composition of gingival crevicular fluid sampled from male adolescents with no destructive periodontitis: baseline data of a longitudinal study.
J. Periodontal Res.
25:6-16[CrossRef][Medline].
|
| 5.
|
Genco, C. A.,
J. Potempa,
J. Mikolajczyk-Pawlinska, and J. Travis.
1999.
Role of gingipains R in the pathogenesis of Porphyromonas gingivalis mediated periodontal disease.
Clin. Infect. Dis.
28:456-465[Medline].
|
| 6.
|
Genco, C. A.,
B. M. Odusanya,
J. Potempa,
J. Mikolajczyk-Pawlinska, and J. Travis.
1998.
A peptide domain on gingipain R1 which confers immunity against Porphyromonas gingivalis infection in mice.
Infect. Immun.
66:4108-4114[Abstract/Free Full Text].
|
| 7.
|
Gharbia, S. E., and H. N. Shah.
1991.
Utilization of aspartate, glutamate and their corresponding peptides by Fusobacterium nucleatum and Porphyromonas gingivalis.
Curr. Microbiol.
22:159-163.
|
| 8.
| Grenier, D., P. Gauthier, P. Plamondon, K. Nakayama,
and D. Mayrand. Studies on the aminopeptidase activities of
Porphyromonas gingivalis. Oral Microbiol. Immunol., in
press.
|
| 9.
|
Henskens, Y. M. C.,
U. van der Velden,
E. C. I. Veerman, and A. V. Nieuw Amerongen.
1993.
Protein, albumin and cystatin concentrations in saliva of healthy subjects and of patients with gingivitis or periodontitis.
J. Periodontal Res.
28:43-48[CrossRef][Medline].
|
| 10.
|
Holt, S.,
L. Kesavalu,
S. Walker, and C. A. Genco.
1999.
Virulence factors of Porphyromonas gingivalis.
Periodontol. 2000
20:168-238[Medline].
|
| 11.
|
Ismaiel, M. O.,
J. Greenman, and J. Scully.
1988.
Serum antibodies against the trypsin-like protease of Bacteroides gingivalis in periodontitis.
J. Periodontal Res.
23:193-198[CrossRef][Medline].
|
| 12.
|
Kuramitsu, H. K.
1998.
Proteases of Porphyromonas gingivalis: what don't they do?
Oral Microbiol. Immunol.
13:263-270[Medline].
|
| 13.
|
Labbé, S.,
D. Grenier,
P. Plamondon,
V.-J. Uitto, and D. Mayrand.
2001.
Effects of dipeptide bestatin on Porphyromonas gingivalis and epithelial cells.
J. Periodontol.
72:714-721[CrossRef][Medline].
|
| 14.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 15.
|
Lamont, R. J., and H. F. Jenkinson.
1998.
Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis.
Microbiol. Mol. Biol. Rev.
62:1244-1263[Abstract/Free Full Text].
|
| 16.
|
Makela, M.,
E. Soderling,
K. Paunio,
J. Talonpoika, and T. Hyyppa.
1991.
Protein composition of crevicular fluid before and after treatment.
Scand. J. Dent. Res.
99:413-423[Medline].
|
| 17.
|
Masuda, K.,
M. Yoshioka,
D. Hinode, and R. Nakamura.
1999.
Characterization of arginine carboxypeptidase from Porphyromonas gingivalis.
J. Dent. Res.
78:507.
|
| 18.
|
Mayrand, D., and D. Grenier.
1985.
Detection of collagenase activity in oral bacteria.
Can. J. Microbiol.
31:134-138[Medline].
|
| 19.
|
Milner, P.,
J. Batten, and M. A. Curtis.
1996.
Development of a simple chemically defined medium for Porphyromonas gingivalis: requirement for -ketoglutarate.
FEMS Microbiol. Lett.
140:125-130[Medline].
|
| 20.
|
Nakayama, K.,
T. Kadowaki,
K. Okamoto, and K. Yamamoto.
1995.
Construction and characterization of arginine-specific cysteine proteinase (Arg-gingipain)-deficient mutants of Porphyromonas gingivalis.
J. Biol. Chem.
270:23619-23626[Abstract/Free Full Text].
|
| 21.
|
Page, R. C.,
M. Lantz,
G. R. Persson,
S. Houston,
S. Lukehart,
M. Jeffcoat,
L. Mancl,
A. Weinberg,
P. Braham, and R. Darveau.
1999.
Immunization with Porphyromonas gingivalis cysteine protease attenuates alveolar bone loss.
J. Dent. Res.
78:294.
|
| 22.
|
Shah, H. N., and S. E. Gharbia.
1993.
Batch culture and physiological properties, p. 85-103.
In
H. N. Shah, D. Mayrand, and R. J. Genco (ed.), Biology of the species Porphyromonas gingivalis. CRC Press, Inc., Boca Raton, Fla.
|
| 23.
|
Shi, Y.,
D. B. Ratnayake,
K. Okamoto,
N. Abe,
K. Yamamoto, and K. Nakayama.
1999.
Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis: construction of mutants with a combination of rgpA, rgpB, kgp, and hagA.
J. Biol. Chem.
274:17955-17960[Abstract/Free Full Text].
|
| 24.
|
Slots, J., and M. Ting.
1999.
Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment.
Periodontol. 2000
20:82-121[Medline].
|
| 25.
|
Smalley, J. W., and A. J. Birss.
1997.
Albumin and hemalbumin degradation by Porphyromonas gingivalis.
Oral Microbiol. Immunol.
12:254-258[Medline].
|
| 26.
|
Vaughan, L. C., and T. D. Thomas.
1982.
Arginine metabolism in lactic streptococci.
J. Bacteriol.
150:1024-1032[Abstract/Free Full Text].
|
Infection and Immunity, August 2001, p. 5166-5172, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5166-5172.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nagano, K., Murakami, Y., Nishikawa, K., Sakakibara, J., Shimozato, K., Yoshimura, F.
(2007). Characterization of RagA and RagB in Porphyromonas gingivalis: study using gene-deletion mutants. J Med Microbiol
56: 1536-1548
[Abstract]
[Full Text]
-
Davey, M. E., Duncan, M. J.
(2006). Enhanced Biofilm Formation and Loss of Capsule Synthesis: Deletion of a Putative Glycosyltransferase in Porphyromonas gingivalis.. J. Bacteriol.
188: 5510-5523
[Abstract]
[Full Text]
-
Bodet, C., Piche, M., Chandad, F., Grenier, D.
(2006). Inhibition of periodontopathogen-derived proteolytic enzymes by a high-molecular-weight fraction isolated from cranberry. J Antimicrob Chemother
57: 685-690
[Abstract]
[Full Text]
-
Yun, P. L. W., Decarlo, A. A., Chapple, C. C., Hunter, N.
(2005). Functional Implication of the Hydrolysis of Platelet Endothelial Cell Adhesion Molecule 1 (CD31) by Gingipains of Porphyromonas gingivalis for the Pathology of Periodontal Disease. Infect. Immun.
73: 1386-1398
[Abstract]
[Full Text]
-
Grenier, D., Roy, S., Chandad, F., Plamondon, P., Yoshioka, M., Nakayama, K., Mayrand, D.
(2003). Effect of Inactivation of the Arg- and/or Lys-Gingipain Gene on Selected Virulence and Physiological Properties of Porphyromonas gingivalis. Infect. Immun.
71: 4742-4748
[Abstract]
[Full Text]